- Multiplex assay that allows simultaneous amplification of the most frequent insertion variants (subtypes A, B and D) in exon 12 of the NPM1 gene.
- The results obtained in this test allow to confirm the diagnosis of the patient. This assay is not optimal for the study of minimal residual disease (MRD) in AML patients.
- The detection limit has been set at 10%.
- Includes an endogenous control to confirm sample quality and integrity.
- It includes a positive control that allows the amplification of the NMP1-Type A variant, which guarantees the functionality of the PCR system.
- It complies with the quality requirements specified by ISO 13845 and ISO 14001 in relation to the materials used in its manufacturing process.
- For in vitro diagnostic use.
Description
Detection of the most frequent insertion mutations (subtypes A, B and D) in exon 12 of the NPM1 gene associated with Acute Myeloid Leukemia with normal cytogenetics (CN-AML)
Format
24 rxn
Technology
Real-time PCR
Reference
IMG-235
Compatible equipment
7500 FAST Real-Time PCR System (ThermoFisher), StepOne Real-Time PCR System (Thermo Fisher), CFX96 Real-Time PCR System (BioRad)
This assay uses a combination of oligonucleotides and fluorescent hydrolysis probes in a validated assay to detect the presence of mutations in the NPM1 gene along with the endogenous gene, b-globin, in a genomic DNA sample.
- Amount of DNA: 50 ng total
- Sample type: Peripheral blood (Germinal)
- Number of reactions per sample: 1
- Number of targets: 3
- Manual working time: 30 min
- Duration of the PCR program: 1 h
- Compatible cyclers: real-time PCR cycler with FAMTM and VIC®
Related kits
Imegen-NPM1
Fill in the form to request this kit.
Call us at +34 963 212 340Or write to us at info@healthincode.com
